8-K: Precision BioSciences Announces Positive Clinical Data and First Quarter 2025 Financial Results

Precision BioSciences reports encouraging clinical data from its ARCUS platform and provides a business update alongside its Q1 2025 financial results, highlighting progress in gene editing therapies.

Summary

• Precision BioSciences announced its first quarter 2025 financial results and provided a business update.
• The company reported new clinical data for two programs utilizing ARCUS, validating the safety and efficacy of its in vivo gene editing approach.
• Initial data from the Phase 1 ELIMINATE-B trial evaluating PBGENE-HBV was announced, with initial safety data presented at EASL and ongoing clinical updates anticipated throughout 2025.
• The U.S. FDA granted Fast Track Designation to PBGENE-HBV for chronic Hepatitis B (HBV).
• Precision is accelerating PBGENE-DMD, targeting an IND/CTA filing in 2025 with clinical data expected in 2026.
• The company expects its cash runway to extend into the second half of 2026, enabling data readouts from PBGENE-HBV and PBGENE-DMD.
• As of March 31, 2025, Precision had approximately $100 million in cash, cash equivalents, and restricted cash.
• Total revenues for the quarter ended March 31, 2025, were less than $0.1 million, compared to $17.6 million for the same period in 2024.
• Research and development expenses were $13.6 million for the quarter ended March 31, 2025, compared to $13.3 million for the same period in 2024.
• Net loss was $20.6 million, or $(2.21) per share, for the quarter ended March 31, 2025, compared to a net income of $8.6 million, or $1.70 per share, for the same period in 2024.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the clinical progress and regulatory milestones achieved, but tempered by the financial losses and revenue decline. The extended cash runway and prioritization of key programs are encouraging.

Positives

• Clinical data validates the safety and efficacy of the ARCUS platform.
• PBGENE-HBV showed a substantial reduction in Hepatitis B surface antigen (HBsAg) in two of the three participants following the first administration at the lowest dose level.
• PBGENE-HBV received Fast Track Designation from the FDA, potentially expediting its development.
• PBGENE-DMD is being prioritized and accelerated, indicating confidence in its potential.
• The company has a cash runway extending into the second half of 2026, providing financial stability for ongoing research and development.
• PBGENE-DMD demonstrated the ability to target key muscle types involved in the progression of DMD and significant, durable functional improvement in a humanized DMD mouse model.
• The ELIMINATE-B trial was cleared to commence Phase 1 clinical trials in the U.S. and the U.K.

Negatives

• Total revenues decreased significantly to less than $0.1 million for the quarter ended March 31, 2025, compared to $17.6 million for the same period in 2024.
• The company reported a net loss of $20.6 million for the quarter ended March 31, 2025, compared to a net income of $8.6 million for the same period in 2024.
• Development of PBGENE-3243 is paused to accelerate PBGENE-DMD and maintain operational capability.

Risks

• The company's ability to successfully develop and commercialize its product candidates is subject to various risks and uncertainties.
• Clinical trial results may not be indicative of future outcomes.
• Competition in the gene editing field could impact the company's success.
• The company's reliance on the ARCUS technology poses a risk if the technology proves to be less effective than other genome-editing technologies.
• The company's limited operating history and ability to assess the safety and efficacy of its product candidates present challenges.
• The company's ability to procure sufficient funding to advance its programs is subject to market conditions and other factors.

Future Outlook

Precision BioSciences expects its cash runway to extend into the second half of 2026, enabling data readouts from PBGENE-HBV and PBGENE-DMD. The company plans to file an IND and/or CTA for PBGENE-DMD in 2025, with clinical data expected in 2026. They also plan to share updates on full cohorts including antiviral efficacy at different dose levels as each cohort is completed following three dose administrations and appropriate follow up.

Management Comments

• We started 2025 with strong momentum and a focus on generating impactful clinical data across our in vivo gene editing pipeline, said Michael Amoroso, Chief Executive Officer of Precision BioSciences.
• Early this year, data from the OTC-HOPE trial provided the first clinical validation for ARCUS in vivo gene insertion following a complete response in an infant with OTC-deficiency.
• The Phase 1 ELIMINATE-B trial evaluating PBGENE-HBV, our lead program for chronic Hepatitis B, is progressing as planned.
• We look forward to sharing additional updates from the ELIMINATE-B trial throughout 2025, including antiviral efficacy data from each cohort upon completion of three dose administrations.
• We have prioritized this program to be our second wholly owned program with a target IND and/or clinical trial application (CTA) in 2025, continued Mr. Amoroso.
• This reinforces our commitment to delivering transformative therapies in genetic diseases with the highest unmet need and driving near and long-term value while being prudent stewards of capital.

Industry Context

Precision BioSciences is operating in the competitive gene editing space, focusing on in vivo gene editing therapies. The company's ARCUS platform aims to offer advantages over other technologies with its unique cutting mechanism, smaller size, and simpler structure. The progress of PBGENE-HBV and PBGENE-DMD, along with the Fast Track Designation for PBGENE-HBV, positions the company to potentially address significant unmet needs in chronic Hepatitis B and Duchenne muscular dystrophy.

Comparison to Industry Standards

• The Fast Track designation for PBGENE-HBV is a positive sign, as it can expedite the review process compared to standard regulatory pathways.
• The company's focus on in vivo gene editing aligns with a growing trend in the industry, as it offers the potential for one-time curative treatments.
• Companies like CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics are also developing gene editing therapies, but Precision's ARCUS platform offers a differentiated approach.
• The reported cash runway into the second half of 2026 is crucial for sustaining operations and advancing clinical programs, which is a key metric investors monitor in the biotech industry.

Stakeholder Impact

• Shareholders may be impacted by the financial performance and progress of clinical programs.
• Employees are affected by the company's strategic decisions and operational capabilities.
• Patients with chronic Hepatitis B and Duchenne muscular dystrophy stand to benefit from the development of new therapies.
• Suppliers and collaborators are impacted by the company's research and development activities.

Next Steps

• Precision plans to share additional updates from the ELIMINATE-B trial throughout 2025, including antiviral efficacy data.
• The company targets filing an IND and/or CTA for PBGENE-DMD in 2025, with clinical data expected in 2026.
• Precision plans to escalate to higher dose levels and next cohorts in the ELIMINATE-B clinical trial.
• iECURE expects to complete enrollment in the OTC-HOPE study in 2025 and anticipates complete data from the trial in the first half of 2026.

Key Dates

Keywords

gene editing, ARCUS, PBGENE-HBV, PBGENE-DMD, clinical trials, financial results, Precision BioSciences, Fast Track Designation, ELIMINATE-B, IND/CTA